RxDoctor Payments Data

Eric Watson, MD

Internal Medicine · Saint George, SCNPI 1952474769

Payments from drug & device makers

$2,040in general payments, 2019–2025

Across 57 payments — averaging $35.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$889
  • GSK$344
  • Amarin Pharma, Inc.$162
  • Lilly USA, LLC$130
  • Esperion Therapeutics, Inc.$113
  • AbbVie$84
  • plus $319 from 10 others

What the payments were for

  • Food & beverage$2,034100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,040 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$100,973
Medicare patients
218
Services billed
1,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$166,806
EliquisApixaban165$123,447
MounjaroTirzepatide95$97,860
FarxigaDapagliflozin Propanediol80$78,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$70,758
XareltoRivaroxaban73$53,090
LinzessLinaclotide60$44,882
RybelsusSemaglutide32$32,758
OxycontinOxycodone Hcl13$28,363
JanuviaSitagliptin Phosphate14$19,933
JardianceEmpagliflozin27$17,167
TrulicityDulaglutide14$13,154
Rosuvastatin Calcium584$10,937
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen289$8,762
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen227$7,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$16$199,564173 claims
PfizerEliquis$30$123,447165 claims
Lilly USA, LLCMounjaro, Trulicity$130$111,014109 claims
AstraZenecaFarxiga$889$78,01880 claims
GSKTrelegy Ellipta, Breo Ellipta$344$76,50298 claims
Johnson & JohnsonXarelto$64$53,09073 claims
AbbVieLinzess$84$44,88260 claims
Boehringer IngelheimJardiance$31$17,16727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Saint George

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →